Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical equipment and techniques have already greatly improved the postoperative safety of patients. However, considering individual differences between patients, some still at risk due to possible complications during hospitalization or after discharge from the hospital, it will no doubt generate a large healthcare burden. This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and treatment effect and efficiency in this field, reducing mortality, medical costs, and medical burden, while opening up new avenues for interdisciplinary clinical practice and scientific research exploration.
Study Type
OBSERVATIONAL
Enrollment
5,000
Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe First People's Hospital of Neijiang
Neijiang, Sichuan, China
RECRUITINGUnfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of \>2.
Time frame: 10 days after the procedure
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
Time frame: 3 months
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
Time frame: 6 months
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
Time frame: 12 months
Unfavorable neurological outcome (mRS>2)
Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
Time frame: 24 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at discharge,defined as changes in thinking, emotion, will and behavior.
Time frame: 10 days after the procedure
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 3 months, defined as changes in thinking, emotion, will and behavior.
Time frame: 3 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 6 months, defined as changes in thinking, emotion, will and behavior.
Time frame: 6 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 12 months, defined as changes in thinking, emotion, will and behavior.
Time frame: 12 months
Cognitive deficits
Number of patients experiencing a unfavorable neurological outcome at 24 months, defined as changes in thinking, emotion, will and behavior.
Time frame: 24 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at discharge.
Time frame: 10 days after the procedure
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 3 months.
Time frame: 3 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 6 months.
Time frame: 6 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 12 months.
Time frame: 12 months
Major adverse cardiac or cerebrovascular events
Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 24 months.
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.